الفهرس Only 14 pages are availabe for public view
 |  | from | 176 |  |  |
| | | from | 176 | | |
Abstract
Background: Uterine corpus cancer is the most common gynecological malignancy in developed countries and the second most common after cancer cervix in developing countries. Non-Endometrioid malignancies have higher risks for recurrence and distant metastasis that may address the need for adjuvant therapy. Ways to improve treatment results needs a better assessment of different prognostic factors to find the best treatment modality. Objective: The aim of this retrospective study is to identify the clinic-pathological data, prognostic factors and different treatment modality results which affect diseasefree survival (DFS) and overall survival (OS) of Non-endometrioid malignancies of the uterine corpus. Patients and methods: All patients{u201F} files presented to NCI in the period between January 2009 to December 2013 having Non-Endometrioid malignancy of uterine corpus were retrieved and reviewed. Results and conclusions: The most frequently encountered pathology was carcinosarcoma for Nonendometrioid carcinoma accounting for 48.7% and Leiomyosarcoma for uterine sarcoma accounting for 46.7%. Patients most frequently presented with stage I disease. The most dominant site of metastasis on follow up was the lung. The most VII frequently used treatment modality for Non-endometrioid carcinoma was surgery alone (35%), while (23.6%) of the studied patients underwent surgery followed by EBRT in which (25.7%) received Brachytherapy after EBRT, (22.3%) of patients underwent surgery followed by EBRT and chemotherapy and (14.4%) underwent surgery followed by chemotherapy. While for uterine sarcoma, the most common treatment modality was surgery alone (73.3%), while (16.6%) of the studied patients underwent surgery followed by EBRT in which (33.3%) received Brachytherapy after EBRT, (3.3%) of patients underwent surgery followed by EBRT and chemotherapy and (6.6%) underwent surgery followed by chemotherapy